News

The Latest Information about i-FACTOR and Cerapedics

Cerapedics Announces Commercial Launch of i-FACTOR®+ Matrix in Canada

Find out more

Cerapedics Announces Canadian Approval of its next-generation bone graft

Canada will be the first commercial market to launch i-FACTOR®+ Matrix

Find out more

Cerapedics Announces FDA approval of an IDE supplement

The IDE Supplement allows for a reduction in the total number of patients required to be enrolled in the ASPIRE IDE Study on P15-L bone graft in the lumbar spine.

Find out more

Cerapedics Announces Results from Clinical Trial of i-FACTOR® Peptide Enhanced Bone Graft in Lumbar Fusion Surgery

Data published in The Spine Journal show elderly patients undergoing non-instrumented fusion achieve statistically significantly higher fusion rate with i-FACTOR bone graft compared to allograft

Find out more

Cerapedics Announces FDA Approval of PMA Supplement Based on Two-Year Clinical Data

i-FACTOR® Peptide Enhanced Bone Graft continues to demonstrate statistical superiority to autologous bone in cervical spine surgery

Find out more

Cerapedics Announces Expansion of Colorado Headquarters

Ortho-biologics company adds 10,000 square feet and doubles employee headcount at Denver metropolitan headquarters

Find out more

New V.P. of Clinical and Market Development

Cerapedics Appoints Patrick O’Connor as Vice President of Clinical and Market Development

Find out more

Cerapedics announces ISASS bone grafting policy statement

Society states company's drug-device combination technology shown to be safe and effective as autograft replacement with compelling clinical evidence .

Find out more

Cerapedics named company of the year

MedTech Outlook’s Top 10 Orthopedic Solution Providers.

Find out more

Cerapedics named as a finalist for company of the year

The finalists are in for the 10th annual PM360 Trailblazer Awards. PM360, a leading health-marketing industry trade magazine, will honor the pharmaceutical and medical device industries’ most influential innovators.

Find out more